

Ananya Choudhury

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4100989/publications.pdf>

Version: 2024-02-01

109
papers

3,736
citations

147801

31
h-index

138484

58
g-index

111
all docs

111
docs citations

111
times ranked

5217
citing authors

#	ARTICLE	IF	CITATIONS
1	Use of angiotensin converting enzyme inhibitors is associated with reduced risk of late bladder toxicity following radiotherapy for prostate cancer. <i>Radiotherapy and Oncology</i> , 2022, 168, 75-82.	0.6	10
2	Development and validation of a hypoxia-associated signature for lung adenocarcinoma. <i>Scientific Reports</i> , 2022, 12, 1290.	3.3	6
3	Biomarkers in muscle invasive bladder cancer. <i>Advances in Clinical Chemistry</i> , 2022, 107, 265-297.	3.7	5
4	Overview of health-related quality of life and toxicity of non-small cell lung cancer patients receiving curative-intent radiotherapy in a real-life setting (the REQUITE study). <i>Lung Cancer</i> , 2022, 166, 228-241.	2.0	5
5	Evaluation of the palliative radiotherapy pathway in a single institute: Can an MR Linac improve efficiency?. <i>Journal of Medical Imaging and Radiation Sciences</i> , 2022, 53, S44-S50.	0.3	7
6	The impact of an educational tool in cervix image registration across three imaging modalities. <i>British Journal of Radiology</i> , 2022, 95, .	2.2	0
7	Radiotherapy respiratory motion management in hepatobiliary and pancreatic malignancies: a systematic review of patient factors influencing effectiveness of motion reduction with abdominal compression. <i>Acta Oncologica</i> , 2022, 61, 833-841.	1.8	5
8	To see or not to see: Evaluation of magnetic resonance imaging sequences for use in MR Linac-based radiotherapy treatment. <i>Journal of Medical Imaging and Radiation Sciences</i> , 2022, 53, 362-373.	0.3	6
9	Trimodal Therapy. , 2021, , 257-280.		0
10	Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials. <i>Lancet Oncology</i> , The, 2021, 22, 246-255.	10.7	73
11	Developing Tumor Radiosensitivity Signatures Using LncRNAs. <i>Radiation Research</i> , 2021, 195, 324-333.	1.5	10
12	Dosimetric Predictors of Radiotherapy-Induced Lymphocytopenia in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2021, 16, e11-e12.	1.1	1
13	A miRNA signature predicts benefit from addition of hypoxia-modifying therapy to radiation treatment in invasive bladder cancer. <i>British Journal of Cancer</i> , 2021, 125, 85-93.	6.4	6
14	Lost in application: Measuring hypoxia for radiotherapy optimisation. <i>European Journal of Cancer</i> , 2021, 148, 260-276.	2.8	21
15	Development of a method for generating SNP interaction-aware polygenic risk scores for radiotherapy toxicity. <i>Radiotherapy and Oncology</i> , 2021, 159, 241-248.	0.6	11
16	Can Hypofractionation and Immune Modulation Coexist?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 742-744.	0.8	1
17	Patterns of Care, Tolerability, and Safety of the First Cohort of Patients Treated on a Novel High-Field MR-Linac Within the MOMENTUM Study: Initial Results From a Prospective Multi-Institutional Registry. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 867-875.	0.8	37
18	Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer. <i>BMC Urology</i> , 2021, 21, 96.	1.4	5

#	ARTICLE	IF	CITATIONS
19	Photons, Protons, SBRT, Brachytherapy—What Is Leading the Charge for the Management of Prostate Cancer? A Perspective From the GU Editorial Team. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 1114-1121.	0.8	4
20	Long-Term Outcomes of Radical Radiation Therapy with Hypoxia Modification with Biomarker Discovery for Stratification: 10-Year Update of the BCON (Bladder Carbogen Nicotinamide) Phase 3 Randomized Trial (ISRCTN45938399). <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 1407-1415.	0.8	33
21	What Is the Significance of Variant Histology in Urothelial Carcinoma?. <i>European Urology Focus</i> , 2020, 6, 653-663.	3.1	126
22	Magnetic resonance—guided radiation therapy: A review. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2020, 64, 163-177.	1.8	104
23	External Beam Radiation Therapy (EBRT) and High-Dose-Rate (HDR) Brachytherapy for Intermediate and High-Risk Prostate Cancer: The Impact of EBRT Volume. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 525-533.	0.8	26
24	A pilot study on dosimetric and radiomics analysis of urethral strictures following HDR brachytherapy as monotherapy for localized prostate cancer. <i>British Journal of Radiology</i> , 2020, 93, 20190760.	2.2	8
25	EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort. <i>European Urology</i> , 2020, 77, 223-250.	1.9	132
26	The Horse is at the Stable Door: Management of N1M0 Prostate Cancer. <i>Clinical Oncology</i> , 2020, 32, 199-208.	1.4	3
27	Selection of endogenous control genes for normalising gene expression data derived from formalin-fixed paraffin-embedded tumour tissue. <i>Scientific Reports</i> , 2020, 10, 17258.	3.3	10
28	A Deep Learning Approach Validates Genetic Risk Factors for Late Toxicity After Prostate Cancer Radiotherapy in a REQUITE Multi-National Cohort. <i>Frontiers in Oncology</i> , 2020, 10, 541281.	2.8	15
29	The role of palliative radiotherapy in bladder cancer: a narrative review. <i>Annals of Palliative Medicine</i> , 2020, 9, 4294-4299.	1.2	8
30	Therapeutic Radiographers at the Helm: Moving Towards Radiographer-Led MR-Guided Radiotherapy. <i>Journal of Medical Imaging and Radiation Sciences</i> , 2020, 51, 364-372.	0.3	28
31	Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19. <i>Advances in Radiation Oncology</i> , 2020, 5, 26-32.	1.2	19
32	FROGG patterns of practice survey and consensus recommendations on radiation therapy for MIBC. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2020, 64, 882-893.	1.8	4
33	Radiation Fractionation Schedules Published During the COVID-19 Pandemic: A Systematic Review of the Quality of Evidence and Recommendations for Future Development. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 379-389.	0.8	47
34	Clinical Guidance for the Management of Patients with Urothelial Cancers During the COVID-19 Pandemic—Rapid Review. <i>Clinical Oncology</i> , 2020, 32, 347-353.	1.4	10
35	Toll-Like Receptor Agonists and Radiation Therapy Combinations: An Untapped Opportunity to Induce Anticancer Immunity and Improve Tumor control. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 27-37.	0.8	22
36	Radiobiologically derived biphasic fractionation schemes to overcome the effects of tumour hypoxia. <i>British Journal of Radiology</i> , 2020, 93, 20190250.	2.2	2

#	ARTICLE	IF	CITATIONS
37	Flattening the Curve of Prostate Cancer Progression: Accurate Detection and Safe Ablation. International Journal of Radiation Oncology Biology Physics, 2020, 107, 609-612.	0.8	0
38	Management of bladder cancer in older patients: Position paper of a SIOG Task Force. Journal of Geriatric Oncology, 2020, 11, 1043-1053.	1.0	46
39	Ten-Year Outcomes of Moderately Hypofractionated Salvage Postprostatectomy Radiation Therapy and External Validation of Contemporary Multivariable Nomogram for Biochemical Failure. International Journal of Radiation Oncology Biology Physics, 2020, 107, 288-296.	0.8	27
40	Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19. Advances in Radiation Oncology, 2020, 5, 659-665.	1.2	149
41	External Validation of a Predictive Model for Acute Skin Radiation Toxicity in the REQUITE Breast Cohort. Frontiers in Oncology, 2020, 10, 575909.	2.8	1
42	External Validation of a Predictive Model for Acute Skin Radiation Toxicity in the REQUITE Breast Cohort. Frontiers in Oncology, 2020, 10, 575909.	2.8	10
43	Assessing localized dosimetric effects due to unplanned gas cavities during pelvic MR-guided radiotherapy using Monte Carlo simulations. Medical Physics, 2019, 46, 5807-5815.	3.0	13
44	Palliative Radiation Therapy in Bladder Cancer—Importance of Patient Selection: A Retrospective Multicenter Study. International Journal of Radiation Oncology Biology Physics, 2019, 105, 389-393.	0.8	23
45	Clinical Oncology in Sri Lanka: Embracing the Promise of the Future. International Journal of Radiation Oncology Biology Physics, 2019, 105, 466-470.	0.8	16
46	Predictive Biomarkers for Muscle-invasive Bladder Cancer: The Search for the Holy Grail Continues. European Urology, 2019, 76, 69-70.	1.9	3
47	MRE11 as a Predictive Biomarker of Outcome After Radiation Therapy in Bladder Cancer. International Journal of Radiation Oncology Biology Physics, 2019, 104, 809-818.	0.8	23
48	REQUITE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer. Radiotherapy and Oncology, 2019, 138, 59-67.	0.6	53
49	Organ preservation in bladder cancer: an opportunity for truly personalized treatment. Nature Reviews Urology, 2019, 16, 511-522.	3.8	31
50	Formidable Scenarios in Urothelial and Variant Cancers of the Urinary Tract. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 262-275.	3.8	3
51	SABR versus conventional fractionation regimens in NSCLC. Lancet Oncology, The, 2019, 20, e231.	10.7	0
52	Post-treatment lymphocytopenia, integral body dose and overall survival in lung cancer patients treated with radical radiotherapy. Radiotherapy and Oncology, 2019, 135, 115-119.	0.6	42
53	STAMPEDE: Is Radiation Therapy to the Primary a New Standard of Care in Men with Metastatic Prostate Cancer?. International Journal of Radiation Oncology Biology Physics, 2019, 104, 33-35.	0.8	8
54	The role of biomarkers in bladder preservation management of muscle-invasive bladder cancer. World Journal of Urology, 2019, 37, 1767-1772.	2.2	8

#	ARTICLE	IF	CITATIONS
55	Comparison of intensity modulated radiotherapy plan optimisation methods for a 1.5 T MR-Linac. Journal of Applied Clinical Medical Physics, 2019, 20, 43-49.	1.9	6
56	Acute Epithelial Toxicity Is Prognostic for Improved Prostate Cancer Response to Radiation Therapy: A Retrospective, Multicenter, Cohort Study. International Journal of Radiation Oncology Biology Physics, 2018, 101, 957-963.	0.8	5
57	The Efficacy and Safety of Conventional and Hypofractionated High-Dose Radiation Therapy for Prostate Cancer in an Elderly Population: A Subgroup Analysis of the CHHiP Trial. International Journal of Radiation Oncology Biology Physics, 2018, 100, 1179-1189.	0.8	33
58	Bladder cancer and the National Cancer Data Base: New insight or misinformation?. Cancer, 2018, 124, 1105-1107.	4.1	5
59	The hypoxia marker CAIX is prognostic in the UK phase III Vortex-Biobank cohort: an important resource for translational research in soft tissue sarcoma. British Journal of Cancer, 2018, 118, 698-704.	6.4	20
60	Development and Validation of a 28-gene Hypoxia-related Prognostic Signature for Localized Prostate Cancer. EBioMedicine, 2018, 31, 182-189.	6.1	132
61	Relapsing Prostate Cancer: Castrate or Cure?. International Journal of Radiation Oncology Biology Physics, 2018, 100, 1095-1096.	0.8	3
62	The anti-PD-1 era – an opportunity to enhance radiotherapy for patients with bladder cancer. Nature Reviews Urology, 2018, 15, 251-259.	3.8	27
63	Magnetic Resonance Imaging-Guided Adaptive Radiation Therapy: A ‘Game Changer’ for Prostate Treatment?. International Journal of Radiation Oncology Biology Physics, 2018, 100, 361-373.	0.8	132
64	Validation of a hypoxia related gene signature in multiple soft tissue sarcoma cohorts. Oncotarget, 2018, 9, 3946-3955.	1.8	35
65	Exploring trends in advanced bladder cancer using the NCDB: turning data into information and information into insight. Translational Andrology and Urology, 2018, 7, 754-756.	1.4	0
66	Radiotherapy for High-grade T1 Bladder Cancer. European Urology Focus, 2018, 4, 506-508.	3.1	10
67	The Potential Value of MRI in External-Beam Radiotherapy for Cervical Cancer. Clinical Oncology, 2018, 30, 737-750.	1.4	22
68	Outcomes of radiosensitisation in elderly patients with advanced bladder cancer. Radiotherapy and Oncology, 2018, 129, 499-506.	0.6	10
69	The Future of Radiotherapy in Bladder Cancer. , 2018, , 123-129.		0
70	Magnetic Resonance Imaging-Guided Radiation Therapy: A Short Strengths, Weaknesses, Opportunities, and Threats Analysis. International Journal of Radiation Oncology Biology Physics, 2018, 101, 1057-1060.	0.8	83
71	Comparing Clinical Outcomes for Radium-223: Do Older Patients Do Worse?. International Journal of Radiation Oncology Biology Physics, 2017, 98, 955-957.	0.8	8
72	The predictive and prognostic value of tumour necrosis in muscle invasive bladder cancer patients receiving radiotherapy with or without chemotherapy in the BC2001 trial (CRUK/01/004). British Journal of Cancer, 2017, 116, 649-657.	6.4	9

#	ARTICLE	IF	CITATIONS
73	A Gene Signature for Selecting Benefit from Hypoxia Modification of Radiotherapy for High-Risk Bladder Cancer Patients. <i>Clinical Cancer Research</i> , 2017, 23, 4761-4768.	7.0	107
74	“But We Are Already Geriatric Oncologists” Why Older Patients Need a Special Approach (A View) <i>TJ</i> 2017, 98, 964-965.	0.8	2
75	Using the Malthus programme to predict the recruitment of patients to MR-linac research trials in prostate and lung cancer. <i>Radiotherapy and Oncology</i> , 2017, 122, 159-162.	0.6	6
76	Protecting Low-Risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 515-517.	0.8	3
77	Technical Note: Investigating the impact of field size on patient selection for the 1.5T MR-Linac. <i>Medical Physics</i> , 2017, 44, 5667-5671.	3.0	23
78	Association of Survival Benefit With Docetaxel in Prostate Cancer and Total Number of Cycles Administered. <i>JAMA Oncology</i> , 2017, 3, 68.	7.1	33
79	Tolerability of Concurrent Chemoradiation Therapy With Gemcitabine (GemX), With and Without Prior Neoadjuvant Chemotherapy, in Muscle Invasive Bladder Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 732-739.	0.8	26
80	The Rationale for Post-Operative Radiation in Localized Bladder Cancer. <i>Bladder Cancer</i> , 2017, 3, 19-30.	0.4	22
81	The MRI-Linear Accelerator Consortium: Evidence-Based Clinical Introduction of an Innovation in Radiation Oncology Connecting Researchers, Methodology, Data Collection, Quality Assurance, and Technical Development. <i>Frontiers in Oncology</i> , 2016, 6, 215.	2.8	100
82	Development and Validation of Consensus Contouring Guidelines for Adjuvant Radiation Therapy for Bladder Cancer After Radical Cystectomy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 78-86.	0.8	46
83	Fit Patient with Nonmetastatic Castration-resistant Prostate Cancer, Lower Urinary Tract Symptoms, and Severe Recurrent Haematuria. <i>European Urology Focus</i> , 2016, 2, 477-478.	3.1	0
84	Adjuvant Chemotherapy Is More Suitable Than Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer Patients Treated With Radical Chemoradiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 614-616.	0.8	6
85	Concurrent gemcitabine and radiotherapy for the treatment of muscle-invasive bladder cancer: A pooled individual data analysis of eight phase III trials. <i>Radiotherapy and Oncology</i> , 2016, 121, 193-198.	0.6	36
86	Bladder Preservation for Muscle Invasive Bladder Cancer. <i>Bladder Cancer</i> , 2016, 2, 151-163.	0.4	25
87	A combined single high-dose rate brachytherapy boost with hypofractionated external beam radiotherapy results in a high rate of biochemical disease free survival in localised intermediate and high risk prostate cancer patients. <i>Radiotherapy and Oncology</i> , 2016, 121, 299-303.	0.6	20
88	Molecular Biomarkers in Muscle-Invasive Bladder Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 705-706.	0.8	2
89	Biomarkers of Tumour Radiosensitivity and Predicting Benefit from Radiotherapy. <i>Clinical Oncology</i> , 2015, 27, 561-569.	1.4	52
90	The treatment of periarticular soft tissue sarcoma following neo-adjuvant radiotherapy: a cohort study. <i>World Journal of Surgical Oncology</i> , 2015, 13, 108.	1.9	2

#	ARTICLE	IF	CITATIONS
91	Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 417-425.	10.7	137
92	Parametrized rectal dose and associations with late toxicity in prostate cancer radiotherapy. <i>British Journal of Radiology</i> , 2015, 88, 20150110.	2.2	7
93	Genome-wide association study yields variants at 20p12.2 that associate with urinary bladder cancer. <i>Human Molecular Genetics</i> , 2014, 23, 5545-5557.	2.9	46
94	Delivering adaptive radiotherapy to the bladder during radical treatment. <i>Journal of Radiotherapy in Practice</i> , 2013, 12, 195-202.	0.5	2
95	Necrosis predicts benefit from hypoxia-modifying therapy in patients with high risk bladder cancer enrolled in a phase III randomised trial. <i>Radiotherapy and Oncology</i> , 2013, 108, 40-47.	0.6	54
96	Outcome and patient-reported toxicity in localised prostate cancer treated with dose-escalated hypofractionated intensity-modulated radiotherapy. <i>Journal of Radiotherapy in Practice</i> , 2013, 12, 326-333.	0.5	0
97	Single-fraction high-dose-rate (HDR) brachytherapy boost and hypofractionated radiation for intermediate- and high-risk prostate cancer: A report of toxicity from a single center experience.. <i>Journal of Clinical Oncology</i> , 2012, 30, 112-112.	1.6	1
98	BLADDER PRESERVATION MULTIMODALITY THERAPY AS AN ALTERNATIVE TO RADICAL CYSTECTOMY FOR TREATMENT OF MUSCLE INVASIVE BLADDER CANCER. <i>BJU International</i> , 2011, 108, E313.	2.5	5
99	Recurrence patterns of locally advanced head and neck squamous cell carcinoma after 3D conformal (chemo)-radiotherapy. <i>Radiation Oncology</i> , 2011, 6, 54.	2.7	67
100	Phase II Study of Conformal Hypofractionated Radiotherapy With Concurrent Gemcitabine in Muscle-Invasive Bladder Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 733-738.	1.6	155
101	European genome-wide association study identifies SLC14A1 as a new urinary bladder cancer susceptibility gene. <i>Human Molecular Genetics</i> , 2011, 20, 4268-4281.	2.9	134
102	A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer. <i>Nature Genetics</i> , 2010, 42, 415-419.	21.4	169
103	MRE11 Expression Is Predictive of Cause-Specific Survival following Radical Radiotherapy for Muscle-Invasive Bladder Cancer. <i>Cancer Research</i> , 2010, 70, 7017-7026.	0.9	184
104	Targeting homologous recombination using imatinib results in enhanced tumor cell chemosensitivity and radiosensitivity. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 203-213.	4.1	95
105	Polymorphisms in DNA Repair Genes, Smoking, and Bladder Cancer Risk: Findings from the International Consortium of Bladder Cancer. <i>Cancer Research</i> , 2009, 69, 6857-6864.	0.9	107
106	Analysis of variants in DNA damage signalling genes in bladder cancer. <i>BMC Medical Genetics</i> , 2008, 9, 69.	2.1	38
107	Similar Treatment Outcomes for Radical Cystectomy and Radical Radiotherapy in Invasive Bladder Cancer Treated at a United Kingdom Specialist Treatment Center. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 70, 456-463.	0.8	121
108	In Reply to Dr. Rosario et al.. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 1602.	0.8	0

#	ARTICLE	IF	CITATIONS
109	Radiation and New Molecular Agents Part I: Targeting ATM-ATR Checkpoints, DNA Repair, and the Proteasome. <i>Seminars in Radiation Oncology</i> , 2006, 16, 51-58.	2.2	97